Galapagos NV (GLPG) PT Raised to $33 at RBC Capital Feb 24, 2026 02:21PM
Raymond James on Galapagos NV (GLPG): 'we are constructive on the potential for meaningful business development' Feb 24, 2026 10:21AM
Galapagos winds down cell therapy operations, affecting 365 employees Jan 5, 2026 04:03PM
Galapagos finalizes wind-down of cell therapy operations Jan 5, 2026 04:03PM
Raymond James Reiterates Market Perform Rating on Galapagos NV (GLPG) Dec 19, 2025 04:02AM


Nov 25, 2025 04:42PM Bernstein SocGen Group Initiates Market Perform Rating on Galapagos NV (GLPG:NA) (GLPG)
Oct 22, 2025 08:12AM Galapagos NV (GLPG) PT Raised to $28 at RBC Capital
Oct 22, 2025 06:38AM Leerink Partners Upgrades Galapagos NV (GLPG) to Outperform
Oct 1, 2025 04:03PM Galapagos explores sale of cell therapy business after receiving offers
Jul 24, 2025 12:46PM Raymond James Reiterates Market Perform Rating on Galapagos NV (GLPG)
May 13, 2025 04:45PM Raymond James Reiterates Market Perform Rating on Galapagos NV (GLPG)
Apr 24, 2025 01:49PM Raymond James Reiterates Market Perform Rating on Galapagos NV (GLPG)
Jan 23, 2025 05:20AM Barclays Downgrades Galapagos NV (GLPG:NA) (GLPG) to Underweight
Nov 20, 2024 06:08AM Kepler Cheuvreux Downgrades Galapagos NV (GLPG:NA) (GLPG) to Reduce
Nov 4, 2024 10:02AM Galapagos NV (GLPG:NA) (GLPG) PT Lowered to EUR28 at Deutsche Bank
Oct 31, 2024 12:15PM Galapagos NV (GLPG) PT Lowered to $31 at Morgan Stanley
Sep 9, 2024 12:05PM Leerink Partners Starts Galapagos NV (GLPG) at Market Perform
Aug 2, 2024 01:37PM Galapagos NV (GLPG) PT Lowered to $32 at Morgan Stanley
Jun 17, 2024 10:15AM TD Cowen Reiterates Buy Rating on Galapagos NV (GLPG)
Jun 14, 2024 04:03PM Galapagos (GLPG) presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024